Unibest

Pharmaceutical intermediates

Lifitegrast Intermediates

4 pharmaceutical intermediates for Lifitegrast. Indication: Dry Eye Syndromes.

提交项目All intermediates

About Lifitegrast

Originator
Shire Development Llc
Indication
Dry Eye Syndromes
Approved Date
07/11/2016
DS/DP
03/10/2025

Available intermediates

4 intermediates currently listed for Lifitegrast. Request specifications, documentation or a quotation for any item below.

Lifitegrast intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
benzofuran-6-carboxylic acid77095-51-3//
2-(tert-butoxycarbonyl)-5,7-dichloro-1,2,3,4-tetrahydroisoquinoline-6-carboxylic acid851784-82-2//
5,7-Dichloro-1,2,3,4-Tetrahydroisoquinoline-6-Carboxylic Acid Hydrochloride1289646-93-0//
methyl (S)-2-amino-3-(3-(methylsulfonyl)phenyl)propanoate hydrochloride851785-21-2//

Other programs under L

(LCZ696)LanifibranorLapatinibLarotrectinibLasmiditanLazertinib MesylateLemborexantLenacapavir sodium

Building toward Lifitegrast?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →